Loading Beema Health
Beema Health
Evidence-based guide

Traditional vs GLP-1 Weight Loss: Evidence

An educational comparison of lifestyle approaches and GLP-1 receptor agonist therapy, grounded in peer-reviewed trials and clinical guidelines.

Last updated: 2026-08-24

Want a quick reference point first? Check your BMI.

BMI Calculator

See where your BMI falls, then decide if it's worth a conversation with a licensed provider. For general information only; the below calculator is not a diagnosis and is not part of medical intake.

BMI calculator

Body Mass Index estimates whether your weight falls in a typical range for your height. It's a starting point, not a diagnosis. Your provider looks at your full health picture.

Height

For general information only. It doesn't replace a licensed provider's evaluation, and it isn't part of your medical intake.

1518.5253040

Your BMI

-

UnderweightUnder 18.5
Healthy weight18.5 – 24.9
Overweight25 – 29.9
Obesity30 and above

1.The Traditional Weight Loss Path

The foundation of every evidence-based weight-management strategy (including drug-assisted ones) is a sustained energy deficit combined with behavior change. Traditional methods remain first-line, low-risk, and widely recommended by public-health authorities.

Caloric deficit fundamentals

Weight loss occurs when energy expenditure exceeds energy intake over time. The CDC states that people who lose weight gradually (about 1 to 2 pounds per week) are more likely to keep it off than those who lose weight quickly, and that achieving this pace generally requires reducing caloric intake by roughly 500-1,000 calories per day[1]. The 2013 AHA/ACC/TOS obesity guideline operationalizes the deficit three ways: prescribing 1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men; prescribing a 500-750 kcal/day energy deficit; or prescribing an evidence-based diet that restricts certain food types to create a deficit[2].

Diet approaches

No single macronutrient composition has proven clearly superior when calorie intake is matched. The DIETFITS randomized trial (JAMA, 2018) compared a healthy low-fat versus a healthy low-carbohydrate diet in 609 adults over 12 months and found no statistically significant difference in weight change (−5.3 kg low-fat vs. −6.0 kg low-carb), with wide individual variation in both arms[3]. The 2013 AHA/ACC/TOS guideline reached a consistent conclusion: a variety of dietary approaches produce weight loss “if reduction in dietary energy intake is achieved”[2]. The practical implication is that adherence and sustainability matter more than the specific diet label. Patients should choose an eating pattern they can maintain.

Realistic timelines and rates of weight loss

The AHA/ACC/TOS guideline notes that diet-driven weight loss is typically maximal at about 6 months (a range of roughly 4-12 kg from dietary intervention alone), followed by slow regain thereafter[2]. The Look AHEAD trial, the largest and longest randomized lifestyle-intervention study in adults with type 2 diabetes (n = 5,145), found that the intensive lifestyle-intervention group achieved its maximum weight loss of about 8.5% at year 1 but maintained 4.7% at year 8, versus 2.1% in the control group; at year 8, 50.3% of the intervention group had maintained ≥5% loss[4]. This illustrates the central challenge of the traditional path: initial loss is achievable for most people, but long-term maintenance is difficult and regain is common.

Resistance training's role in preserving lean mass

Any energy deficit causes loss of both fat and lean (muscle) tissue. Resistance training is the best-established countermeasure. A systematic review and meta-analysis of randomized trials in obese older adults found that resistance training reduced caloric-restriction-induced lean-mass loss by 93.5% while still permitting substantial fat loss[5]. Adequate dietary protein (commonly cited at 1.2-1.6 g/kg/day during active weight loss) further supports muscle preservation[16].

Behavioral consistency factors

The AHA/ACC/TOS guideline recommends comprehensive lifestyle programs lasting at least 6 months, delivered in high-intensity format (≥14 sessions in 6 months) by a trained interventionist, as the most effective behavioral structure for durable results[2]. Consistency, self-monitoring, accountability, sleep, and stress management are all cited by the CDC as factors that meaningfully affect long-term success[1].

2.The GLP-1 Path: How It Works

Mechanism of action

GLP-1 (glucagon-like peptide-1) receptor agonists mimic an endogenous intestinal incretin hormone secreted in response to food intake. They act through both central and peripheral pathways[6]:

  • Central (brain): They activate GLP-1 receptors in appetite-regulating regions such as the hypothalamus, reducing hunger and increasing satiety, which lowers overall caloric intake.
  • Peripheral (gut/pancreas): They slow gastric emptying (prolonging fullness after meals), enhance glucose-dependent insulin secretion, and inhibit glucagon release.

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, a mechanism that may contribute to its larger average weight-loss effect[9]. The net physiological change is reduced energy intake driven primarily by decreased appetite and earlier satiety, not by “burning” fat directly[6].

Realistic timelines and average weight loss from major trials
  • Semaglutide 2.4 mg, STEP 1 (Wilding et al., NEJM 2021): Mean weight loss of 14.9% at 68 weeks vs. 2.4% with placebo (both with lifestyle intervention); 86.4% of the semaglutide group achieved ≥5% loss vs. 31.5% placebo[7].
  • Semaglutide, STEP 5 (2-year): −15.2% vs. −2.6% placebo at week 104, showing durability of effect while treatment continues[8].
  • Tirzepatide, SURMOUNT-1 (Jastreboff et al., NEJM 2022): Mean weight loss of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) vs. 2.4% placebo at 72 weeks; 89-96% achieved ≥5% loss[9].
  • Head-to-head, SURMOUNT-5 (Aronne et al., NEJM 2025): In 751 adults, tirzepatide produced −20.2% vs. semaglutide −13.7% at 72 weeks (P<0.001). This is the only randomized head-to-head trial; note it was open-label and industry-funded[10].

Across trials, weight loss typically begins within the first weeks, accelerates during dose titration, and reaches a nadir (plateau) around week 60-72[7],[9].

3.Side-by-Side Comparison

The table below presents figures as reported in each trial or guideline. With the exception of SURMOUNT-5, these are not head-to-head comparisons; the trials enrolled different populations under different protocols. The data are presented to inform, not to rank.

DimensionTraditional (Lifestyle)GLP-1-Assisted
Typical magnitude~8.5% at year 1; ~4.7% maintained at year 8 (Look AHEAD)[4]14.9% (semaglutide, STEP 1) to 22.5% (tirzepatide 15 mg, SURMOUNT-1)[7],[9]
Timeline to peakMaximal ~6 months, then slow regain[2]Nadir ~60-72 weeks[7],[9]
Effort profileHigh, sustained daily behavioral effort (diet + activity + self-monitoring)Weekly injection plus recommended lifestyle changes; GI side effects common during titration
SustainabilityRegain common; about half maintain ≥5% at 8 years[4]Weight loss largely dependent on continued use; regain follows discontinuation[11],[12],[17]
CostLower direct cost (gym, dietitian, food)Higher medication cost (see Section 7)
RiskVery low riskGI side effects; boxed warning for thyroid C-cell tumors; requires provider oversight[16],[26]

4.Muscle Preservation and Lean Mass

An important, evidence-grounded point: some lean-mass loss accompanies all weight loss, whether achieved through diet, medication, or surgery. This is a feature of energy deficit, not a phenomenon unique to GLP-1 drugs.

  • STEP 1 body-composition substudy (semaglutide, DXA): Total lean body mass decreased 9.7% from baseline, but because fat mass fell more (total fat mass −19.3%, visceral fat −27.4%), the proportion of lean mass relative to total body mass actually increased by 3.0 percentage points[13].
  • SURMOUNT-1 substudy (tirzepatide, DXA): Of the weight lost, approximately 75% was fat mass and 25% was lean mass. The same fat-to-lean ratio was observed in the placebo group[14].
  • Network meta-analysis of GLP-1 therapies: Lean-mass loss comprised approximately 25% of total weight loss, which the authors characterize as within the normal range for any weight-loss method[15].
  • Heterogeneity across the literature: Some reviews report a wider range: lean-mass reductions of roughly 15% to 40-60% of total weight lost, depending on the rate of loss, degree of caloric restriction, and whether patients performed resistance exercise[16].

Role of resistance training and protein

The mitigation evidence from traditional weight-loss research applies directly: a meta-analysis in obese older adults found resistance training prevented 93.5% of caloric-restriction-induced lean-mass loss[5], and protein intake of about 1.2-1.6 g/kg/day is commonly recommended during active loss[16]. Pairing GLP-1 therapy with resistance training and adequate protein is a reasonable, evidence-informed strategy to favor fat loss over muscle loss.

For a practical, cited overview of weekly sets, effort, and protein targets, see Resistance Training for Muscle Growth. Those programming defaults come from resistance-training research in healthy adults. They are not a claim that any medication preserves muscle.

5.What Happens After Stopping: Weight Regain

  • STEP 1 trial extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022): In an off-treatment extension of 327 participants, one year after withdrawing semaglutide, participants regained 11.6 percentage points of the 17.3% they had lost, approximately two-thirds of their prior weight loss, resulting in a net loss of 5.6% from baseline at week 120. Cardiometabolic improvements likewise reverted toward baseline[11].
  • STEP 4 (Rubino et al., JAMA, 2021): After a 20-week semaglutide run-in (mean 10.6% loss), participants randomized to switch to placebo gained 6.9% from weeks 20-68, while those who continued semaglutide lost an additional 7.9%, an estimated treatment difference of 14.8 percentage points[12].
  • SURMOUNT-4 (Aronne et al., JAMA, 2024): After a 36-week tirzepatide lead-in, participants who continued treatment achieved a further mean change of −19.4% (weeks 36-88) versus substantial regain in those switched to placebo; continued treatment maintained and augmented weight loss[17].
  • SURMOUNT-4 post hoc analysis (Horn et al., JAMA Internal Medicine, 2026): Among participants who had lost ≥10% and then stopped tirzepatide, most regained ≥25% of the weight they had lost within one year, accompanied by reversal of cardiometabolic gains[18].

Interpretation: These data consistently support the clinical framing of obesity as a chronic, relapsing condition in which weight loss is largely dependent on ongoing treatment, analogous to how blood pressure rises again when antihypertensive medication is stopped. This is a factual, well-substantiated pattern and is not a marketing claim.

6.Drug and Dose Overview (Educational Only)

  • Semaglutide (Wegovy): FDA-labeled titration: Treatment begins at 0.25 mg once weekly and escalates approximately every 4 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), reaching the 2.4 mg maintenance dose at about week 17. The 0.25 mg starting dose is explicitly a tolerability (initiation) dose, not a therapeutic maintenance dose. Labeling advises that if a patient does not tolerate a step, escalation may be delayed. A 7.2 mg high-dose (Wegovy HD) option was FDA-approved in 2025 for eligible patients who tolerate 2.4 mg[19].
  • Tirzepatide (Zepbound): labeling: Structured dose escalation to a maximum tolerated dose, commonly 10 or 15 mg once weekly, following a “start low, go slow” schedule[17].

The gradual escalation exists specifically to reduce the risk of gastrointestinal adverse reactions, which are most common during and shortly after each dose increase[19],[26].

7.Cost Comparison

Traditional weight-loss costs
  • Gym membership: GoodRx (2025) reports Americans spend an average of about $65/month (“$65 per month, or $780 annually”), with budget chains at $10-$30/month and premium gyms $150-$300+/month[20].
  • Registered dietitian: ConsumerAffairs (2026) reports consultations average $100-$200, with initial visits commonly $100-$250 and follow-ups $50-$150[21].
  • Meal plans / programs: Roughly $75-$300/month depending on customization and level of coaching[21].
Brand-name GLP-1 list prices (before discounts)
  • Wegovy (semaglutide): List price $1,349.02 per 28-day package (per Novo Nordisk/NovoCare)[22].
  • Zepbound (tirzepatide): List price roughly $1,086/month (per CNBC, Dec 2025)[22].
  • Ozempic (semaglutide, diabetes): List price $1,027.51[22].
Manufacturer cash-pay programs
  • Wegovy (NovoCare): New self-pay patients pay $199/month for the first two monthly fills of the 0.25 mg and 0.5 mg doses (through December 31, 2026), then $349/month; Wegovy HD 7.2 mg is $399/month[22].
  • Zepbound (LillyDirect): Single-dose vials at $299/month (2.5 mg starting dose), $399/month (5 mg), and $449/month for all other approved doses (reduced from a prior $499) as of December 1, 2025[22],[29].
Beema Health compounded GLP-1 pricing
  • Compounded semaglutide: $199/month, billed monthly with no platform membership fee.
  • Compounded tirzepatide: $297/month, billed monthly with no platform membership fee.

Compared with the brand-name list prices above (roughly $1,000-$1,350 per month before discounts)[22], Beema Health's compounded cash-pay pricing is about one-fifth the cost of brand-name drugs (for example, $199/month vs. Ozempic list pricing of $1,027.51, or about 1/5). Multi-month plans include a semaglutide first-month promo ($99 first month on a 3-month plan, then $199/mo for months 2 and 3) and tirzepatide maintenance from $249.5/mo on a 6-month plan, with a new-patient starter pack at $199/mo). A one-time $100 checkout coupon (once per patient) applies on eligible multi-month plans (not the starter pack). Shipping and labs, when applicable, are shown separately. A prescription is never guaranteed.

Food spending: one patient example

That patient explained that his monthly grocery bill halved, from about $600/month previously to about $300/month after starting GLP-1 treatment (about $300/month saved on groceries).

He also described eating out less often: roughly 2 times per month while on GLP-1, at about $50 per meal (about $100/month), compared with roughly 12 times per month before starting GLP-1 at the same ~$50 per meal (about $600/month). That is about $500/month saved on eating out.

In his accounting, those changes added up to about $800/month in food-related savings ($500 dining out + $300 groceries). He said that savings was significantly greater than the monthly cost of compounded tirzepatide for both of them (Beema Health compounded tirzepatide is $297/month per person, or $594/month for two).

Appetite, grocery habits, and dining-out habits vary widely. Individual results differ, and food spending can move for many reasons unrelated to medication. Use this only as one person's report, not as expected savings.

8.Frequently Asked Questions

Who is eligible for GLP-1 weight-management medication?
FDA indicates adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (examples named in labeling include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease). Eligibility, contraindications, and appropriateness are determined by a licensed provider, not by any calculator or marketing page.
What are the common side effects?
Gastrointestinal effects are most common and usually mild-to-moderate. In pooled STEP 1-3 data, nausea occurred in 43.9% of the semaglutide group (vs. 16.1% placebo), diarrhea 29.7%, vomiting 24.5%, and constipation 24.2%; 99.5% of GI events were non-serious, and 4.3% of patients permanently discontinued due to GI events. In SURMOUNT-1, nausea ranged from 24.6% to 33.3% depending on dose, with GI-related discontinuation under about 8%. GLP-1 medications carry a boxed warning for thyroid C-cell tumors (based on rodent data; no confirmed human causation) and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Rarer risks include pancreatitis and gallbladder events. Any symptoms should be discussed promptly with a provider.
How do compounded medications differ from brand-name?
Compounded drugs are prepared by pharmacies rather than manufactured and FDA-approved as finished products. They have not undergone FDA review for safety, effectiveness, or quality. They are not FDA-approved and are not therapeutically equivalent to branded products.
How does telehealth prescribing work?
A licensed provider reviews the patient's medical history and eligibility (often through an asynchronous online intake), determines whether treatment is clinically appropriate, and (if so) may issue a prescription that is fulfilled by a licensed pharmacy partner. Beema Health does not practice medicine, prescribe, or dispense medication; those functions rest entirely with independent licensed providers and pharmacies.
Is one medication "better" than another?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide (20.2% vs. 13.7%) and had a lower GI-related discontinuation rate. However, averages are not individual outcomes, and the most appropriate medication for any person (including whether medication is appropriate at all) is a clinical decision.

9.References

Full reference list (28 sources)
  1. Centers for Disease Control and Prevention. Steps for Losing Weight / Losing Weight. cdc.gov.
  2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014;129(25 Suppl 2):S102-S138.
  3. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss (DIETFITS). JAMA. 2018;319(7):667-679.
  4. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring). 2014;22(1):5-13.
  5. Sardeli AV, et al. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018.
  6. Moiz A, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways. The American Journal of Medicine. 2025.
  7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
  8. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
  10. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
  11. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
  12. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
  13. Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of STEP 1. Journal of the Endocrine Society. 2021.
  14. Look M, et al. Body composition changes during weight reduction with tirzepatide (SURMOUNT-1 substudy). Diabetes, Obesity and Metabolism. 2025.
  15. Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024.
  16. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with GLP-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024.
  17. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
  18. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal (SURMOUNT-4 post hoc analysis). JAMA Internal Medicine. 2026;186(2):157-167.
  19. Wegovy (semaglutide) injection: FDA Prescribing Information. Novo Nordisk (DailyMed / FDA labeling).
  20. GoodRx (2025), average U.S. gym-membership cost data.
  21. ConsumerAffairs. How much does a dietitian cost? (2026). Consultation and follow-up cost ranges.
  22. NovoCare. Wegovy (semaglutide) cost, coverage, and self-pay pricing.
  23. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
  24. U.S. Food and Drug Administration. Compounding and GLP-1 shortage-resolution determinations (2024-2026).
  25. FDA labeling and eligibility criteria (Wegovy, Zepbound); NIDDK overview of prescription medications to treat overweight and obesity.
  26. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2021.
  27. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), adverse-event data. N Engl J Med. 2022.
  28. Eli Lilly. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials (self-pay pricing effective December 1, 2025).

Ready to explore whether care may be appropriate for you?

Get Started

See also Safety & eligibility, compounded semaglutide, and compounded tirzepatide.